Integra LifeSciences Analysts Cut Their Forecasts After Q2 Results
Portfolio Pulse from Avi Kapoor
Integra LifeSciences (NASDAQ:IART) reported better-than-expected Q2 earnings but lowered its FY24 guidance. Analysts have subsequently downgraded their ratings and reduced price targets for the stock.
July 30, 2024 | 3:36 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Integra LifeSciences reported Q2 earnings that beat estimates but lowered its FY24 guidance. Analysts downgraded the stock and reduced price targets.
Despite beating Q2 earnings estimates, Integra LifeSciences lowered its FY24 guidance, which led to analysts downgrading the stock and reducing price targets. This is likely to have a negative short-term impact on the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100